Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,549.64
(
-0.86%
)
US TECH 100
23,442.80
(
-1.17%
)
Dow Jones
45,781.57
(
-0.52%
)
Brent Oil
106.95
(
2.41%
)
Bitcoin
69,684.01
(
-0.31%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 85586

Wednesday, 11/04/2009 10:50:18 PM

Wednesday, November 04, 2009 10:50:18 PM

Post# of 257262
IDIX 2009-2010 News Flow

[Updated for start of phase-2 IDX184 trial (#msg-43179141).]


HCV


4Q09: Start phase-1 trial of IDX375. (A CTA was submitted during 3Q09.)

4Q09: Submit IND/CTA for IDX316. Start phase-1 trial in 1Q010.

Late 2009 or more likely (IMO) 1H10: Ink IDX184 partnership.

Mid 2010: Report top-line phase-2 data for IDX184.

Nov 2010: Present complete phase-2 data for IDX184 at AASLD.

2010(?): Submit IND/CTA for lead compound from NS5A program.


HIV

Early 2010: GSK* starts phase-2 IDX899 trial.

*GSK is the operator of ViiV Healthcare, the HIV joint venture with PFE (#msg-43254006).


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today